Acurx Pharmaceuticals, Inc. (ACXP) closed the last trading session at $5.21, gaining 172.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17 indicates a 226.3% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $12.12. While the lowest estimate of $10.00 indicates a 91.9% increase from the current price level, the most optimi ...

Company Overview - Acurx Pharmaceuticals, Inc. (ACXP) is part of the Medical sector, which includes 925 individual stocks and currently holds a Zacks Sector Rank of 10 among 16 groups [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which consists of 444 companies and is ranked 140 in the Zacks Industry Rank [6] Performance Metrics - Acurx Pharmaceuticals has returned 93.2% year-to-date, significantly outperforming the average loss of 3.2% in the Medical group [4] - The Zacks Consensus Estimate for ACXP's full-year earnings has increased by 42.5% over the past quarter, indicating a positive trend in analyst sentiment [4] Comparative Analysis - Another stock in the Medical sector, Apyx Medical (APYX), has returned 4.9% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Apyx Medical belongs to the Medical - Products industry, which has seen a decline of 10.3% this year, contrasting with Acurx's strong performance [7]

Management View - Acurx Pharmaceuticals, Inc. (ACXP) reported a receipt of $1.4 million in gross proceeds from the execution of Series F Warrants in October 2025 [2] - The company is preparing to launch a pivotal recurrent CDI trial in the second half of 2026 while also strengthening its ibezapolstat pipeline [2]

Financial Data and Key Metrics Changes - The company ended 2025 with cash totaling $7.6 million, an increase from $3.7 million as of December 31, 2024 [14] - The net loss for Q4 2025 was $1.6 million, or $0.73 per diluted share, compared to a net loss of $2.8 million, or $3.29 per diluted share for Q4 2024 [18] - For the full year 2025, the net loss was $8 million, or $5.32 per diluted share, down from a net loss of $14.1 million, or $17.45 per share in 2024 [18] Business Line Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to decreased manufacturing and consulting costs [15] - For the full year 2025, R&D expenses were $1.8 million, a significant decrease from $5.4 million in 2024, attributed to lower manufacturing and consulting costs [16] - General and administrative expenses for Q4 2025 were $1.3 million, down from $2 million in Q4 2024, mainly due to reduced compensation and professional fees [16] Market Data and Key Metrics Changes - The company is focusing on the recurrent CDI market, which affects approximately 500,000 patients annually in the U.S., resulting in about 30,000 deaths and a public health cost burden of approximately $5 billion [21] Company Strategy and Development Direction - The company is launching a new clinical trial program for ibezapolstat in patients with recurrent CDI, aiming to shift treatment from two agents to one [9] - The company plans to request FDA approval for ibezapolstat under the Limited Population Pathway for Antibacterial and Antifungal Drugs guidance [10] - The company is pursuing funding opportunities for its phase 3 clinical trial programs and considering alternative financial pathways [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the challenging macroeconomic environment and industry sector while continuing to develop ibezapolstat's competitive profile [13] - The FDA's potential shift to a one-trial requirement for registration is seen as a positive development that could benefit the company's clinical development programs [11] Other Important Information - The company received a new patent for its Pol IIIC inhibitors, extending to December 2039, which covers composition of matter and method of use [11] - The company has approximately $7 million to $8 million left on its equity line of credit, which may support ongoing clinical trials [40] Q&A Session Summary Question: What is the primary endpoint for the recurrent CDI trial and its cost? - The primary endpoint is prevention of recurrence, with an evaluation period of eight weeks, and the trial cost is estimated to be between $4 million and $5 million [27][36] Question: When will the pilot study for recurrent CDI start and conclude? - Enrollment is expected to start in the second half of 2026, with full enrollment anticipated in 12-15 months [37] Question: How many patients are projected for the phase 3 trial for recurrent CDI? - The current projection is between 360 and 400 patients for a single trial in the recurrent CDI indication [42] Question: Is U.S.-based manufacturing a focus for the company? - Yes, the company is in discussions with government agencies regarding U.S.-based manufacturing, which is important for potential funding [46] Question: How real is the FDA's one-trial requirement? - Management is optimistic about the one-trial requirement being formalized, which could change the clinical trial landscape [73]

Financial Data and Key Metrics Changes - The company ended 2025 with cash totaling $7.6 million, an increase from $3.7 million as of December 31, 2024 [12] - The net loss for Q4 2025 was $1.6 million, or $0.73 per diluted share, compared to a net loss of $2.8 million, or $3.29 per diluted share for Q4 2024 [16] - For the full year 2025, the net loss was $8 million, or $5.32 per diluted share, down from a net loss of $14.1 million, or $17.45 per share in 2024 [16] Business Line Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to decreased manufacturing and consulting costs [13] - For the full year 2025, R&D expenses totaled $1.8 million, a significant decrease from $5.4 million in 2024, attributed to lower manufacturing and consulting costs [14] - General and administrative expenses for Q4 2025 were $1.3 million, down from $2 million in Q4 2024, mainly due to reduced compensation-related costs and professional fees [14] Market Data and Key Metrics Changes - The company presented at IDWeek in Atlanta, highlighting the potential of ibezapolstat and its microbiome-sparing properties, which could position it favorably in the market [4][5] - The FDA's recent announcement regarding a one-trial requirement for registration could significantly impact the company's clinical development programs and market entry strategy [10] Company Strategy and Development Direction - The company is launching a new clinical trial program for ibezapolstat in patients with recurrent CDI, aiming to shift treatment paradigms from two agents to one [7][19] - The company is pursuing funding opportunities for its phase 3 clinical trial programs and exploring alternative financial pathways [11] - The focus on U.S.-based manufacturing aligns with government interests in public-private partnerships, potentially enhancing funding opportunities [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the macroeconomic challenges and emphasized the competitive profile of ibezapolstat [12] - The potential for ibezapolstat to be the first agent to demonstrate clinical success in both treating and preventing recurrent CDI was highlighted as a significant opportunity [19] - The company is optimistic about the implications of the FDA's new guidance on clinical trial requirements for its development programs [10] Other Important Information - The company received a new patent for its Pol IIIC inhibitors, extending protection to December 2039 [10] - The clinical program for ibezapolstat has received fast track designations from the FDA, enhancing its development prospects [11] Q&A Session Summary Question: What is the primary endpoint for the recurrent CDI trial and its cost? - The primary endpoint is prevention of recurrence, with an evaluation period of eight weeks and a trial cost estimated between $4 million and $5 million [22][32] Question: When will the pilot study start and conclude? - Enrollment for the pilot study is expected to begin in the second half of 2026, with full enrollment anticipated to take 12-15 months [33] Question: How many patients will be needed for the phase 3 trial? - The current projection for the phase 3 trial in recurrent CDI is between 360 and 400 patients, depending on data from the open-label trial [37] Question: Is U.S.-based manufacturing a focus for the company? - Yes, the company is engaging with government agencies regarding U.S.-based manufacturing, which is seen as beneficial for securing funding [41]

Core Insights - Acurx Pharmaceuticals reported significant advancements in its clinical programs and financial results for the year and fourth quarter ended December 31, 2025, highlighting the readiness to advance its antibiotic candidate, ibezapolstat, to Phase 3 trials for treating recurrent C. difficile infections (rCDI) [1][2] Financial Results - The company ended Q4 2025 with cash totaling $7.6 million, an increase from $3.7 million as of December 31, 2024 [1] - Research and development expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to reduced manufacturing and consulting costs [1] - General and administrative expenses for Q4 2025 were $1.3 million, a decrease from $2.0 million in Q4 2024, attributed to lower compensation-related costs and professional fees [2] - The net loss for Q4 2025 was $1.6 million or $0.73 per diluted share, compared to a net loss of $2.8 million or $3.29 per diluted share in Q4 2024 [2] Clinical Developments - Acurx's clinical program for the broader CDI patient population is set to advance to Phase 3 international pivotal clinical trials, potentially benefiting from a new FDA standard that may allow for a single pivotal trial for registration [1] - The company is launching a new clinical trial program for ibezapolstat in patients with rCDI, which aims to shift treatment paradigms from two agents to one [1] - Ibezapolstat has shown a 96% clinical cure rate in a Phase 2 trial for acute CDI, with no recurrence while preserving the gut microbiome [1] Intellectual Property and Collaborations - Acurx received a new patent for its Pol IIIC inhibitors, extending protection until December 2039 [1] - The company published significant research results in Nature Communications, demonstrating the binding of ibezapolstat to its target, marking a milestone in its collaboration with Leiden University Medical Center [1] Market Position and Future Outlook - Acurx is well-positioned to commence its international Phase 3 registration program, having received positive regulatory guidance from both the FDA and EMA [2] - The company’s lead product candidate, ibezapolstat, is recognized as a Qualified Infectious Disease Product (QIDP) and has received Fast Track designation from the FDA, highlighting its potential in addressing urgent public health threats [2]

Financial Performance - The company has incurred significant net losses of $8.0 million for the year ended December 31, 2025, and $14.1 million for the year ended December 31, 2024, with no revenue generated from product sales [200]. - The company anticipates continuing to incur net losses for the foreseeable future and may never achieve or maintain profitability [200]. - The company has expressed substantial doubt about its ability to continue as a going concern due to significant accumulated deficits and negative operating cash flows [203]. - As of December 31, 2025, the company had approximately $7.6 million in cash and expects to require substantial additional funding to continue operations [205]. Funding and Capital Structure - The company completed an IPO in June 2021, raising net cash proceeds of $14.8 million, and has since conducted several direct offerings, raising additional funds [205]. - The company has established an "At-the-Market" offering program with an aggregate offering price of up to $17.0 million, of which $9.2 million has been raised [205]. - The company expects to issue additional capital stock in the future, which will dilute existing stockholders' ownership interests [359]. Product Development and Commercialization - The company relies on the success of its lead product candidate, ibezapolstat, for the treatment of CDI, and any delays in commercialization could materially harm its business [196]. - The company is reliant on the successful commercialization of its lead product candidate, ibezapolstat, for CDI treatment, which is critical for generating product revenues [211]. - The ability to generate product revenues depends on successful clinical development, regulatory approvals, and establishing manufacturing and distribution capabilities [213]. - The company may face challenges in obtaining regulatory approval for its product candidates, which could impair its ability to generate revenue [204]. - The company may experience delays or inability to commercialize ibezapolstat if it fails to meet key development milestones [222]. - Enrollment challenges in clinical trials could delay the development and commercialization of product candidates, impacting the company's ability to generate revenue [252]. - The time required to obtain FDA and other regulatory approvals is unpredictable, often taking many years, which could hinder the company's market entry [254]. - Any delays or failures in obtaining required approvals could adversely affect the company's revenue generation capabilities from product candidates [257]. Regulatory and Compliance Risks - The company faces significant risks related to product liability and clinical trials, which could adversely affect its financial condition [219]. - Ongoing regulatory oversight is required for marketed drugs, including compliance with U.S. and foreign requirements, which could limit or withdraw approvals if not adhered to [259]. - The FDA has significant post-market authority, including the ability to require labeling changes and post-market studies based on new safety information [260]. - The company is subject to numerous foreign regulatory requirements that may affect clinical trials, manufacturing, and marketing authorization [258]. - Compliance with new healthcare legislation, such as the ACA, could be time-intensive and expensive, potentially impacting the company's business operations [270]. - Legislative and regulatory proposals aimed at reducing healthcare costs could materially harm the company's business and financial condition [295]. Market and Competitive Environment - The company must navigate competitive pressures from larger, better-capitalized firms in the pharmaceutical industry [226]. - The success of ibezapolstat will depend on market acceptance, pricing, and competition with other CDI therapies [216]. - The company’s product candidates may face competition from generic drugs sooner than anticipated, impacting future revenue and profitability [264]. - The Hatch-Waxman Amendments allow the FDA to approve generic drugs based on previously approved products, which could lead to earlier competition for the company’s products [265]. Operational Challenges - The company lacks a sales and marketing infrastructure and plans to commercialize ibezapolstat in the U.S. with a specialized sales force, while also considering third-party collaborations for other jurisdictions [283]. - The company faces challenges in establishing effective sales and marketing capabilities, which could impact product revenues and profitability [284]. - The company relies on third-party manufacturers for clinical trials and commercialization, which poses risks related to supply, compliance with regulations, and potential delays in product availability [288]. - The company does not have long-term supply agreements and sources raw materials from single-source suppliers, which could lead to supply disruptions if issues arise [288]. Legal and Intellectual Property Risks - The company may face significant expenses and distractions from litigation related to intellectual property claims, which could adversely affect its financial position [305]. - The company may need to license certain intellectual property from third parties, which may not be available on commercially reasonable terms, potentially harming its business [307]. - The company’s ability to enforce its intellectual property rights is crucial for commercialization, and uncertainties in patent litigation could compromise its market competitiveness [308]. Environmental and Climate Risks - Climate change poses significant risks to the company's operations, including physical risks from extreme weather and rising sea levels, which could lead to increased costs and business interruptions [235]. - New legal and regulatory requirements related to climate change may result in expanded carbon pricing, increased compliance costs, and higher operational expenses, potentially impacting the company's profitability [237]. - Future environmental regulations may impair research and production efforts, leading to adverse effects on financial condition and operations [371]. Cybersecurity and Data Privacy - The company faces risks related to cybersecurity incidents that could lead to financial loss and operational disruption [332]. - Compliance with evolving privacy and data protection laws may increase operational costs and complexity for the company [343]. - Non-compliance with privacy regulations, such as the GDPR, could result in fines of up to €20 million or 4% of worldwide revenue, whichever is greater, impacting financial stability [350]. Stockholder and Market Risks - The market price of the company's common stock may be volatile, influenced by various risk factors including clinical trial results and quarterly operating performance [319]. - Significant stockholders collectively own approximately 13% of the company's outstanding shares, potentially influencing corporate decisions [325]. - The company received a notice from Nasdaq on March 25, 2025, indicating non-compliance with the minimum stockholders' equity requirement of $2,500,000 [327]. - The company submitted a Compliance Plan to Nasdaq on May 9, 2025, and regained compliance with the stockholders' equity requirement on August 26, 2025 [328].

Core Viewpoint - Acurx Pharmaceuticals Inc. shares experienced a significant pullback in premarket trading after a substantial rally, indicating potential overbought conditions in the stock market [1][2]. Clinical Update - Acurx Pharmaceuticals announced a new trial for ibezapolstat targeting patients with recurrent C. difficile infection (rCDI), reporting a 96% clinical cure rate from Phase 2 data [3]. - Enrollment for the new study is set to begin in the fourth quarter [3]. Financial Results - The company is expected to report a loss per share of $1.00 for the fourth quarter of 2025, a decrease from a loss of $3.40 per share a year earlier [4]. Strategic Developments - Acurx is advancing into Phase 3 international studies, contingent on funding, and ibezapolstat has received FDA Fast Track and Qualified Infectious Disease Product designations [5]. Technical Analysis - The stock is trading 162.5% above its 20-day simple moving average (SMA) and 48.3% above its 100-day SMA, indicating a strong short-term performance [6]. - Over the past 12 months, shares have declined by 35.16%, and the stock is currently closer to its 52-week lows of $1.33 than its highs of $21.00 [6]. Price Action - During premarket trading, Acurx Pharmaceuticals shares were down 12.95% at $5.24, with key resistance identified at $5.50 and key support at $5.00 [7].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Tilly's, Inc. (TLYS) is up 63% at $2.63 - Bumble Inc. (BMBL) is up 25% at $3.55 - Petco Health and Wellness Company, Inc. (WOOF) is up 16% at $2.80 - Lightwave Logic, Inc. (LWLG) is up 15% at $5.82 - TMD Energy Limited (TMDE) is up 15% at $2.65 - Laird Superfood, Inc. (LSF) is up 11% at $2.77 - Build-A-Bear Workshop, Inc. (BBW) is up 10% at $48.20 - AIFU Inc. (AIFU) is up 9% at $2.09 - BitFuFu Inc. (FUFU) is up 7% at $2.21 - Mexco Energy Corporation (MXC) is up 6% at $12.59 [3] Premarket Losers - Netskope, Inc. (NTSK) is down 15% at $10.25 - FreeCast, Inc. (CAST) is down 14% at $6.82 - Paranovus Entertainment Technology Ltd. (PAVS) is down 14% at $1.95 - ESGL Holdings Limited (OIO) is down 11% at $3.31 - Acurx Pharmaceuticals, Inc. (ACXP) is down 10% at $5.39 - UiPath, Inc. (PATH) is down 7% at $11.45 - Aptera Motors Corp. (SEV) is down 7% at $3.19 - HighPeak Energy, Inc. (HPK) is down 5% at $5.55 - 60 Degrees Pharmaceuticals, Inc. (SXTP) is down 5% at $3.06 - Bit Origin Ltd (BTOG) is down 5% at $2.59 [4]

Group 1 - Acurx Pharmaceuticals Inc shares are experiencing significant gains, with a reported increase of 105.17% to $5.95, attributed to investor reactions to recent developments regarding its antibiotic candidate, ibezapolstat [1][5] - The company is initiating a new clinical trial program for ibezapolstat targeting patients with recurrent C. difficile infection (rCDI) and plans to advance the drug into Phase 3 international studies for the broader CDI population, pending funding [2] - Ibezapolstat has received FDA Fast Track status and is positioned to potentially be the first single agent to treat CDI and prevent recurrent infections, indicating a significant shift in treatment approaches [3] Group 2 - The Relative Strength Index (RSI) for Acurx Pharmaceuticals has surged into the high 80s, indicating that the stock has entered overbought territory following a strong momentum move [4]